Jefferies downgrades Amrize stock rating on margin concerns

Jefferies downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $35.20 from $42.80. Analyst Glynis Johnson cited margin concerns due to rising costs and tough comparisons in 2027. The stock is down 23% year-to-date. Jefferies forecasts continued cost pressures will impact margins. Amrize reported Q3 2026 earnings beating profit estimates but missing revenue targets.

Original reporting
Published Nov 16, 2026, 6:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 6:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AMRZ
Bearish
medium confidence
Mentioned
$AMRZ
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AMRZBearishHigh
01

Why it matters

The downgrade may trigger short‑term selling, but the company's recent earnings beat and acquisition‑driven pricing resilience could limit the decline.

02

Market read

Analyst downgrade with a new price target is a fresh catalyst for AMRZ, likely influencing short‑term price action.

03

What to watch

Potential cost‑pass‑through benefits from upcoming acquisitions are not fully reflected.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

Jefferies issued a new research note lowering its outlook on AMRZ amid rising raw‑material, energy, and freight costs.

Company-level read

Ticker impact

$AMRZBearishMedium confidence
Context

Jefferies downgraded AMRZ to Underperform and cut its price target to $35.20, citing margin pressure.

Expected impact

likely pressure as the market prices in the reduced target

Evidence & confidence

The downgrade is a fresh analyst action with a concrete new target, which typically triggers sell‑side activity.

Market effects

Building‑envelope and cement segments may see broader margin concerns.

U.S. construction‑materials sector could face heightened scrutiny.

Limited to investors tracking analyst coverage of mid‑cap industrial stocks.

Counterpoint

The recent earnings beat and pricing power could offset margin pressure, making the downgrade premature.

Key entities

  • Amrize Ltd

    U.S. listed building‑envelope and cement producer (NYSE:AMRZ).

  • Jefferies

    Equity research firm providing the downgrade.

Related articles

$BETAMed

5 Stocks Analysts Just Downgraded

Wall Street analysts downgraded five stocks: BETA Technologies (BETA), TransUnion (TRU), Molson Coors (TAP), Amrize (AMRZ), and another. Downgrades cited delivery delays, slower growth, soft demand, and cost pressures. BETA's Q3 revenue doubled, but deliveries were delayed. TransUnion's revenue rose 12.2%, but margins slipped. Molson Coors saw net sales fall 1.6% and lowered earnings guidance. Amrize adjusted EBITDA and revenue forecasts due to cost inflation.

Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

$AMRZMed

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.